Literature DB >> 26688949

[Effects of oral cancer-associated fibroblasts on the proliferation, migration, invasion and tube formation to human lymphatic endothelial cells].

Siyuan Chen, Pan Gao, Zheng Chang, Ming Xuan.   

Abstract

OBJECTIVE: To investigate the effects of oral cancer-associated fibroblasts (CAFs) on lymphangiogenesis in oral squamous cell carcinoma (OSCC).
METHODS: CAFs and normal fibroblasts (NFs) were obtained from the tissues of patients with OSCC who did not receive radio-chemotherapy before operation. And the CAFs and NFs were isolated by method of tissue block and identified by immunohistochemical staining. The effects of CAFs (group A) and NFs (group B) to human lymphatic endothelial cells (HLEC) were detected by using a 24-multiwell transwell cell culture chamber. DMEM sugar medium was as blank control group. The number of proliferative, migratory, invasive and tubes of HLEC were counted under inverted phase contrast microscope.
RESULTS: The proliferative number of HLEC of group A for 96, 144, 196 h was significantly higher than that of group B and blank control group, group B higher than blank control group (P<0.01). The migratory and invasive number of HLEC of group A for 96 h was significantly higher than that of group B and blank control group, group B higher than blank control group (P<0.01). The number of tube formation of HLEC of group A for 24 h was significantly higher than that of group B and blank control group, group B higher than blank control group (P<0.01).
CONCLUSION: CAFs promote HLEC's proliferation, migration, invasion, tube formation, and these effects are stronger than NFs.

Entities:  

Mesh:

Year:  2015        PMID: 26688949      PMCID: PMC7030323     

Source DB:  PubMed          Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi        ISSN: 1000-1182


  1 in total

1.  Carcinoma associated fibroblasts derived from oral squamous cell carcinoma promote lymphangiogenesis via c-Met/PI3K/AKT in vitro.

Authors:  Pan Gao; Chunjie Li; Zheng Chang; Xiaoyi Wang; Ming Xuan
Journal:  Oncol Lett       Date:  2017-10-31       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.